DG Health Sinus Severe nasal decongestant recalled for contaminated excipient
Perrigo Company is recalling DG Health Sinus Severe nasal decongestant because the product was manufactured with a contaminated excipient that was recalled from the supplier. Three batches are affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class II recall. No illnesses, injuries, or hospitalizations are reported in the source text. The hazard is a manufacturing process deviation (contaminated excipient) rather than a confirmed harmful substance, making this a precautionary recall.
Plain-English summary
Perrigo Company PLC is recalling DG Health Sinus Severe (Oxymetazoline Hydrochloride 0.05% Nasal Decongestant with Menthol), a non-prescription nasal decongestant sold in 1 FL Oz bottles. The recall affects three batches: 1BK0931 (expiration 12/31/2022), 1CK0900 (expiration 01/31/2023), and 1HK1196 (expiration 02/28/2023).
The product is being recalled because it was manufactured using a contaminated excipient that was itself recalled by the supplier.
The product was distributed nationwide in the USA. Consumers who have purchased affected batches should stop using the product and consult their healthcare provider or poison control if they have questions or concerns about their use.
The recalled product
- Product
- DG HEALTH SINUS SEVERE (OXYMETAZOLINE HYDROCHLORIDE)
- Brand
- DG HEALTH SINUS SEVERE
- Manufacturer
- Perrigo Company PLC
- Category
- Drug — OTC Nasal Decongestant
- Hazard
- contaminated-excipient
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Batch: 1BK0931
- Exp 12/31/2022
- 1CK0900
- Exp 01/31/2023
- 1HK1196
- Exp 02/28/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27